Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1883
Full metadata record
DC FieldValueLanguage
dc.contributor.authorREG NO: BR0121002-
dc.date.accessioned2025-04-29T07:37:04Z-
dc.date.available2025-04-29T07:37:04Z-
dc.date.issued2024-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/1883-
dc.description.abstractINTRODUCTION Chronic obstructive pulmonary disease (COPD) is a significant global health issue, characterized by persistent respiratory symptoms, including dyspnoea, cough, sputum production, and recurrent lower respiratory tract infections. These symptoms degrade the quality of life and precipitate acute exacerbations leading to hospitalizations. A unique subgroup, nonsmoker-COPD (NS-COPD), is defined by the absence of tobacco smoke exposure but includes other environmental or internal illnesses contributing to COPD. This study aims to evaluate the clinical effectiveness of triple therapy (LABA, LAMA, ICS) in managing NS-COPD. OBJECTIVE To evaluate the clinical effectiveness of triple drug therapy combination containing LABA, LAMA and ICS in non-smoking COPD patientsen_US
dc.language.isoen_USen_US
dc.publisherKLE Academy of Higher Education and Research, Belagavien_US
dc.subjectNon-smoker COPD, Triple drug, BODE-index, SGRQ score, Quality of lifeen_US
dc.titleClinical effectiveness of triple drug therapy combination containing laba, lama and ics in non-smoking copd patients- a prospective study over a period of 12 weeksen_US
dc.typeDissertationsen_US
Appears in Collections:Respiratory Medicine MD

Files in This Item:
File Description SizeFormat 
BR0121002.pdf6.01 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.